Canadian Securities ExchangeThe Daily Bell

ASEP Medical Holdings Inc. (CSE:ASEP) w/ Rudy Mazzocchi & Dr. Bob Hancock

New Canadian Stocks

December 14, 2021Newly Listed on the CSE

ASEP Medical Holdings Inc. (CSE:ASEP)

About This Video

ASEP Medical Holdings Inc. is a public company listed on the Canadian Securities Exchange stock market under the symbol ASEP.

ASEP Medical Holdings Inc. has invested in two development stage companies, ABT Innovations Inc. (ABT) and Sepset Biosciences Inc. (Sepset). This consolidation is pursuing the commercialization of proprietary Peptide Technologies by ABT for the treatment of a broad range of infectious diseases, and a novel diagnostic kit developed by Sepset for predicting the early onset of severe sepsis and related organ failure.

Learn more about ASEP Medical Holdings Inc. at https://thecse.com/en/listings/life-sciences/asep-medical-holdings-inc

Subscribe for more great CSE insights and interviews here: https://go.thecse.com/CSETV-Subscribe

STAY CONNECTED WITH THE CSE

=============================

- PODCAST: https://blog.thecse.com/cse-podcasts/

- INSTAGRAM: https://www.instagram.com/canadianexchange/

- LINKEDIN: https://ca.linkedin.com/company/canadian-securities-exchange

- FACEBOOK: https://www.facebook.com/CanadianSecuritiesExchange/

- TWITTER: https://twitter.com/CSE_News

- BLOG: https://blog.thecse.com/

- WEBSITE: https://thecse.com/

- MAGAZINE: https://issuu.com/thecse/docs

Read the TranscriptAuto-generated by YouTube; names and terms may be misspelled.

welcome back thank you for tuning in to another newly listed on the csc clip and today i am talking to two executives from asep medical holdings company is listed on the canadian securities exchange i have with me virtually rudy mazaki rudy is the executive chair as well as the ceo of the company and joining rudy is bob hancock who is the chief operating officer for the company

gents thank you so much for your time today i hope both of you are well good nice pleasure to be here thank you perfect so why don't we get into it bob i'm gonna direct the first question to you why don't you talk to our audience about asap medical holdings what is this company's vision and what do you do so asap is a new company that's addressing major markets related

to a phenomenon called antibiotic failure and the failure of antibiotics together with antibiotic resistant constitute one of the greatest threats to modern medicine and asep derives from the amalgamation of two technology assets sepset biosciences and abt innovations companies that i actually personally found it and is pursuing the clinical validation and commercialization of both a proprietary early sepsis diagnostic test and an anti-biofilm anti-inflammatory therapy to address very large unmet clinical needs got it

now rudy why don't why don't i jump to you with the second question there so what was the strategy behind taking asap medical holdings the public route well as dr hancock indicated so sepsis you know accounts for 19.7 percent of all deaths and biofilm infections two-thirds of all infections it's an enormous global problem causing loss of life of millions of people and chronic issues for survivors

resulting in multi-billion dollar annual burden to our health care systems and many foundations and research funders have recognized the value of our development efforts and it provided the company with a little over 15 million in grant funding to advance our pre-clinical activities so as a privately funded company with exceptional medical researchers directors and management we need to ensure that this technology reaches the global markets becoming a public company

provides us access to that necessary capital as well as market recognition needed to identify the best possible strategic partners who can assist us in the global commercialization of these technologies well said rudy now i want to talk a little bit or dive a little bit more into your background and then talk about the team that you've assembled along with bob to you know move this company and project forward so to start

our founding group is led by dr bob hancock and he's an international renowned academic in microbiology and immunology and also director of the university of british columbia's center for microbial diseases and immunity research he's recruited and built an exceptional medical and pharmaceutical r d research and development staff including fadia syad chief business development officer with and she has an extensive track record of strategic planning and implementing significant projects for global

companies also joining us is dr evan haney he's chief scientific officer he's armed with a phd in biochemistry he's jointly leading our pre-clinical and clinical development efforts with dr hancock so myself as chairman and ceo i have a proven track record of development commercialization and exit of over a dozen med tech and biotechnology companies throughout not only north america but latin america and europe and i currently and previously have

served as chairman and or independent director on several public and private companies boards of directors i've received multiple entrepreneur of the year awards from ernst young and have authored over 100 u.s and international patents in various fields of medical science and finally rolling rounding out our team is our chief financial officer jen gretchen former with kpmg canada and senior financial analyst with qualcomm and she brings years of experience in

accounting and financing with both private public companies rudy what would you say differentiate a company and team like the one you've assembled or you've all assembled from some of your peers in this space well this is really a truly a rare consolidation of both the proprietary diagnostic and therapeutic technologies that are aimed to address this multi-billion dollar global clinical problem and it currently has there are no adequate solutions

so these technologies have been in development for more than a decade now in the hancock laboratory at the university of british columbia as i mentioned previously funded by various u.s and canadian non-dilutive grants and recently supported by sophisticated private corporate and institutional investors so the main significant differentiation is that this company this group of founders and related staff have identified and provided early evidence of solutions for major clinical

problems associated with antibiotic failure so dr hancock are there any milestones you're able to talk about that our viewers can look out for from the company in the coming weeks and months yes we're very excited about the progress we've made and the rates towards work that we're accelerating towards our goal which is of course to be a clinical company rather than an r d company so we've made major

progress in advancing our diagnostic platform towards regulatory 510k filing in the us we've been awarded several key patents and we've formed strategic partnerships and we've performed an in-depth economic analysis of our diagnostic technology and recently demonstrated that our therapy works in predictive animal models for the particular targets we're interested in so the company is preparing a series of upcoming press announcements of developments leading up to our public

listing and we're in the process of identifying and finalizing additional strategic partnerships with company partners contract research organizations and consultants who will perform key pre-clinical tasks and advance our technologies and these are all designed to help expedite the clinical development and commercialization of both the diagnostic and therapeutic technologies of the company the form of the diagnostic will move much more rapidly and we should see very rapid progress in the coming months

and we are also in the process of formally engaging contract research organizations to assist with regulatory filings and to identify our initial clinical sites and their principal investigators so accelerating towards product development dr hancock seems like the company will be having a strong finish to 2021 and probably even stronger start to 2022. yeah we're quite happy with the way things are moving so where can our viewers go to you know

obviously read up on your team the technology the the problem that the company is trying to solve and and you know hopefully sign up for your press releases and get to know a little bit more about why this company is a good investment opportunity well there's a we have a new website that's up and running it's if i do say quite beautiful of course i didn't design it

myself unfortunately so it's www.asepmedical.com and there you can also find a linkages to the technology assets sepset biosciences and abt innovations that also have websites and provide you with a little bit of more of an in-depth view into the actual underpinnings if you like the scientific underpinnings of asep medical so i think investors there have forms that they can fill out and directly request information and we're also

planning to to talk to investors at frequent intervals perfect well gents i i really do appreciate both of you taking the time to not only educate myself a little bit on this problem that that you're finding solutions to and the technology but also our viewers that might be interested in learning more about the company so i appreciate you taking the time i wish you and your team nothing but success in

the coming years and months and years as you move forward with this to everybody watching i'm emil mall i represent the canadian securities exchange and you've been listening to both dr bob hancock who's the chief operating officer as well as mr rudy mazaki he is the executive chair and ceo of asap medical holdings listed on the csc under the symbol asep gents again thank you so much for taking the

time to join us today thank you for tuning in to another newly listed on the csc please feel free to hit like and share this content and hit subscribe if you haven't already

More Newly Listed on the CSE

See them all

Tiger Financial (CSE:BANQ)From Cash to DigitalOct 27, 2026
Caldwell-Lazard CorePlus Infrastructure Fund (CSE:CPIF)Sep 14, 2026
SECUR3D Holdings (CSE:SRD)AI-Powered Brand ProtectionSep 8, 2026
Secur3D Holdings (CSE:SRD)AI-Powered Brand & IP ProtectionAug 20, 2026